THRB and metabolic dysfunction-associated steatohepatitis: This finding prompted the evaluation of resmetirom (MGL-3196), an oral selective TH receptor β1 (THRβ1) agonist, in NASH trials, where it significantly reduced hepatic fat content and achieved >2-point reductions in NASH activity scores compared with those in patients treated with placebo (117,118).